Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  goserelin acetate
Find trials that include:  Any drugs shown
Results 1-21 of 21 for your search:
Start Over
Surgery with or without Docetaxel and Leuprolide Acetate or Goserelin Acetate in Treating Patients with High-Risk Localized Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 90203, NCI-2009-00496, CDR0000526353, NCT00430183
Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0815, NCI-2011-01948, CDR0000648194, NCT00936390
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Exemestane with or without Entinostat in Treating Postmenopausal Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 59
Trial IDs: CLEE011E2301, NCI-2014-02508, NCT02278120
Radiation Therapy, Hormone Therapy, and Docetaxel in Treating Patients with High-Risk Prostate Cancer Previously Treated with Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 85
Trial IDs: 12313, NCI-2011-01380, 4P-06-3, CR00001450, HS-08-00201, NCT00669162
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CR103305, NCI-2013-01912, ARN-509-002, NCT01790126
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Hormone Therapy and Ipilimumab in Treating Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC0253, NCI-2009-01214, NCT00170157
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Akt Inhibitor MK-2206 and Anastrozole with or without Goserelin Acetate in Treating Patients with Stage II-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1139, NCI-2013-00080, 9170, NCT01776008
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0993, NCI-2013-00460, NCT01786265
LHRH Analogue Therapy with Enzalutamide or Bicalutamide in Treating Patients with Metastatic Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-083, NCI-2014-00212, 1311012529, NCT02058706
Androgen Deprivation Therapy with or without Palbociclib Isethionate in Treating Patients with RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.117, NCI-2014-01922, HUM00082715, NCT02059213
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients with Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 135513, NCI-2015-01058, 14-13335, NCI-2015-00154, NCT02168062
Enzalutamide, Radiation Therapy, and Hormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.461, NCI-2013-02283, 080-38340-J90801, 2013-027, 2970, NCT02023463
Mammaglobin-A DNA Vaccine in Treating Patients with Newly Diagnosed Breast Cancer Undergoing Endocrine Therapy before Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201407100, NCI-2014-01457, 14-x092, NCT02204098
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-075, NCI-2015-00742, 1501013723, NCT02472275
mpMRI in Detecting and Goserelin Acetate and Enzalutamide in Treating Patients with Newly Diagnosed Prostate Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0124, NCI-2015-00821, 150124, NCT02430480
Start Over